BioStem Technologies (BioStem Technologies) Debt-to-EBITDA : 2.57 (As of Sep. 2023)

View and export this data going back to 2008. Start your Free Trial

What is BioStem Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioStem Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $4.61 Mil. BioStem Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $1.41 Mil. BioStem Technologies's annualized EBITDA for the quarter that ended in Sep. 2023 was $2.34 Mil. BioStem Technologies's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 2.57.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioStem Technologies's Debt-to-EBITDA or its related term are showing as below:

BSEM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.03 Med: -0.51 Max: -0.12
Current: -1.37

During the past 13 years, the highest Debt-to-EBITDA Ratio of BioStem Technologies was -0.12. The lowest was -8.03. And the median was -0.51.

BSEM's Debt-to-EBITDA is ranked worse than
100% of 279 companies
in the Biotechnology industry
Industry Median: 1.43 vs BSEM: -1.37

BioStem Technologies Debt-to-EBITDA Historical Data

The historical data trend for BioStem Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioStem Technologies Debt-to-EBITDA Chart

BioStem Technologies Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.72

-0.96

-3.53

-8.03

-0.80

BioStem Technologies Quarterly Data
	Sep15	Dec15	Dec16	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Dec21	Mar22	Sep22	Dec22	Mar23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial															-	-	-0.37	-0.82	2.57

Competitive Comparison of BioStem Technologies's Debt-to-EBITDA

For the Biotechnology subindustry, BioStem Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioStem Technologies's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's Debt-to-EBITDA falls into.

BioStem Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioStem Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.051	+	1.038)	/	-6.402
	=	-0.79

BioStem Technologies's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(4.613	+	1.41)	/	2.34
	=	2.57

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.

BioStem Technologies (OTCPK:BSEM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

BioStem Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioStem Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

BioStem Technologies (BioStem Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioStem Technologies Inc (OTCPK:BSEM) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

2836 Center Port Circle, Pompano Beach, FL, USA, 33064

Website

https://www.biostemtechnologies.com

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include RHEO, AEON, OROPRO, VENDAJE, VENDAJE AC, and VENDAJE OPTIC.